Details for Patent: RE44874

Which drugs does patent RE44874 protect, and when does it expire?

Patent RE44874 protects ANORO ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA, and is included in three NDAs.

This patent has fifty-three patent family members in thirty countries.

Summary for Patent: RE44874

Title:	Phenethanolamine derivatives for treatment of respiratory diseases
Abstract:	The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases ##STR00001##
Inventor(s):	Box; Philip Charles (Stevenage, GB), Coe; Diane Mary (Stevenage, GB), Looker; Brian Edgar (Stevenage, GB), Procopiou; Panayiotis Alexandrou (Stevenage, GB)
Assignee:	Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:	13/719,797
Patent Claim Types: see list of patent claims	Compound; Composition; Formulation; Use; Process; Device; Delivery;

Drugs Protected by US Patent RE44874

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes			Y	Y		INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013		RX	Yes	Yes			Y	Y		FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013		RX	Yes	Yes			Y	Y		INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015		RX	Yes	Yes			Y	Y		INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER

Foreign Priority and PCT Information for Patent: RE44874

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0122201.7	Sep 14, 2001
United Kingdom	0126997.6	Nov 9, 2001

PCT Information
PCT Filed	September 11, 2002	PCT Application Number:	PCT/GB02/04140
PCT Publication Date:	March 27, 2003	PCT Publication Number:	WO03/024439

International Family Members for US Patent RE44874

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	036874
Argentina	091595
Austria	417606
Australia	2002326026